Begin your TipRanks Premium journey today. BioCryst (BCRX) Company Description: BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes ...

Operator Good day and Welcome to the BioCryst third-quarter 2024 earnings call. [Operator instructions] Please note this ...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the third quarter ended September 30, 2024, and ...

Several analysts have issued reports on BCRX shares. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform ...

BioCryst Pharmaceuticals ( (BCRX)) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to its investors. BioCryst Pharmaceuticals is a global ...

(BCRX) on Monday reported a loss of $14 million in its third quarter. The Durham, North Carolina-based company said it had a ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $14 million in its third quarter. The Durham, North Carolina-based company said it had ...